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background: Aromatase has been reported to be involved in estrogen biosynthesis and expressed in eutopic and ectopic endome-
trium of endometriosis patients. The objective of the present study was to investigate its expression and localization in three distinct types of
endometriosis.
methods: Human peritoneal, ovarian and rectovaginal endometriotic lesions and matched eutopic endometrium were collected from
patients during laparoscopy. Aromatase protein localization (immunohistochemistry, n ¼ 63) and mRNA expression [quantitative polymer-
ase chain reaction (Q-PCR), n ¼ 64] were assessed.
results: No aromatase protein was detected by immunohistochemistry in either the glandular or stromal compartment of endometriotic
lesions or eutopic endometrium, while it was strong in placental syncytiotrophoblasts, granulosa and internal theca cells from pre-ovulatory
follicles, and luteal cells from corpus luteum. By Q-PCR, low but discernible levels of aromatase expression were found in endometriomas,
probably due to follicular expression. Transcripts for aromatase were barely detectable in only a few peritoneal and rectovaginal endome-
triotic lesions, and a few eutopic endometrium samples, probably due to contaminating surrounding tissues (adipose tissue, intact
peritoneum).
conclusions: Unlike previous studies, we observed no aromatase protein in any of the endometriosis types, and barely detectable
aromatase mRNA expression, suggesting that locally produced aromatase (within endometriotic lesions) may be less implicated in endo-
metriosis development than previously postulated. Potential factors responsible for these discrepancies are discussed.
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Introduction
Endometriosis is one of the most commonly encountered benign
gynecological disorders, characterized by the proliferation of endo-
metrial glands and stroma outside the uterine cavity. The prevalence
of endometriosis varies considerably from study to study. Approxi-
mately 10–15% of reproductive-age women are affected, but
this ﬁgure rises to 40% of women presenting with infertility
(Donnez et al., 2002). We have identiﬁed three types of endo-
metriosis, each with a different pathogenesis: peritoneal, ovarian
and rectovaginal (Nisolle and Donnez, 1997).
The origin and establishment of peritoneal endometriosis can be
explained by the ability of endometrial cells to survive, adhere,
invade tissues and proliferate outside their eutopic location, according
to Sampson’s implantation theory (Sampson, 1927; Nisolle and
Donnez, 1997). In case of ovarian endometriosis, the presence of
mesothelial invagination in continuum with endometriotic tissue
suggests a metaplastic histogenesis of ovarian endometriotic lesions,
but endometriotic cysts may also originate from invagination of super-
ﬁcial endometriotic implants. For rectovaginal nodules, immuno-
cytochemical results show poor differentiation and hormonal
independence of these lesions, and point to a close relationship
with their mesodermal Mu¨llerian origin (Nisolle and Donnez, 1997).
Endometriosis develops mostly in women of reproductive age and
regresses after menopause or ovariectomy, clearly implicating estro-
gen in the establishment and maintenance of this disease. Most phar-
macotherapeutic strategies against endometriosis are therefore
designed to generate a low-estrogen milieu (Mihalyi et al., 2006).
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Aromatase is a key enzyme synthesizing estrogens from androgens,
being involved in the conversion of androstenedione and testosterone
to estrone and estradiol (E2), respectively. Only one single gene
(CYP19) encodes aromatase in mice and humans. In a number of
species, including humans, aromatase expression shows broad tissue dis-
tribution and is found in the placenta, gonads, brain, adipose tissue and
bone (Simpson et al., 1994). This enzyme is localized in the endoplasmic
reticulum of estrogen-producing cells (Bulun et al., 2001; Simpson et al.,
2001). Aromatase expression is essential for reproductive development
and fertility, and aberrant aromatase expression in tissues is associated
with a number of pathological conditions, including gynecomastia and
sexual precocity, tumors of the breast, testes, liver, adrenal cortex and
uterus, and endometriosis (Conley and Hinshelwood, 2001).
Aromatase expression in endometriosis has now been conﬁrmed in
numerous reports at the transcriptional level (Noble et al., 1996;
Dheenadayalu et al., 2002; Ishihara et al., 2003; Heilier et al., 2006a,
b; Matsuzaki et al., 2006; Bukulmez et al., 2007; Dassen et al., 2007;
Kyama et al., 2007; Smuc et al., 2007; Attar et al., 2008; Smuc et al.,
2008), activity level (Kitawaki et al., 1997; Noble et al., 1997; Murakami
et al., 2006; Purohit et al., 2007) and protein level (Kitawaki et al., 1997,
1999a, b; Ishihara et al., 2003; Wo¨lﬂer et al., 2005; Murakami et al.,
2006; Velasco et al., 2006; Acien et al., 2007; Bukulmez et al., 2007;
Hudelist et al., 2007). However, there is no consensus on its localiz-
ation, since some authors found aromatase protein in stromal com-
ponents (Fazleabas et al., 2003; Wo¨lﬂer et al., 2005; Velasco et al.,
2006; Acien et al., 2007), while others demonstrated glandular localiz-
ation (Kitawaki et al., 1997, 1999a, b; Ishihara et al., 2003;Wo¨lﬂer et al.,
2005; Matsuzaki et al., 2006; Fechner et al., 2007; Hudelist et al., 2007).
In addition, the extent of aromatase mRNA expression in endometrio-
tic tissue is controversial, with published papers showing widely varying
values (from barely detectable levels to a 530-fold increase!) (Heilier
et al., 2006b; Bukulmez et al., 2007; Dassen et al., 2007; Kyama et al.,
2007; Smuc et al., 2007; Aghajanova et al., 2009). Moreover, Delvoux
et al. (2008) recently showed a complete absence of aromatase activity
in endometriotic samples.
Aromatase inhibitors (AIs) have been successfully developed and
one of their main therapeutic indications is hormone-dependent
breast cancer (Fabian, 2007). Case reports and pilot studies have
suggested that AIs combined with progestogens or oral contraceptives
may effectively reduce pain symptoms related to the presence of
endometriosis in both post-menopausal women and women of repro-
ductive age (Patwardhan et al., 2008).
The objective of the present study was to investigate aromatase
localization and mRNA expression in three distinct types of endome-
triosis by means of immunohistochemistry and quantitative polymer-
ase chain reaction (Q-PCR). Immunohistochemistry was performed
with anti-aromatase-speciﬁc antibodies to precisely localize the
aromatase enzyme in endometriotic lesions, since there is no consen-
sus in the literature on cell types expressing this enzyme. Q-PCR was
carried out to quantify aromatase expression in endometriotic tissues
(three protocols were compared), as existing studies show great vari-
ation in levels of aromatase expression.
Materials and Methods
The use of human tissue for this study was approved by the Institutional
Review Board of the Universite´ Catholique de Louvain.
Biopsy collection
Biopsies of endometriotic lesions and their matched eutopic endometrium
were taken from 127 patients undergoing laparoscopy (mean age of
patients: 31.8+6.3 years). In 71 cases, patients were in ovulatory
cycles and biopsies were dated as proliferative (n ¼ 35) or secretory
(n ¼ 36). In 56 cases, patients were undergoing hormonal therapy
(47 estroprogestin treatment and 9 GnRH analog therapy). Biopsies
were classiﬁed as peritoneal (n ¼ 64), ovarian (n ¼ 66) or rectovaginal
(n ¼ 65) endometriotic lesions.
Eutopic endometrium was also collected from 10 patients without
endometriosis (presenting for reanastomosis or tubal sterilization) using
an endometrial biopsy curette (mean age of patients: 38.0+6.1 years;
proliferative phase: 3; secretory phase: 7; all in spontaneous cycles).
For 63 of the 127 patients, biopsies were ﬁxed in 4% formaldehyde,
embedded in parafﬁn and serially sectioned (5 mm) for immunohistochem-
ical study. For the remaining 64 patients, fragments of biopsies were frozen
in liquid nitrogen and kept at 2808C until mRNA analysis.
All the biopsies were dissected by an expert gynecologist. Histological
examination of the excised tissue was systematically carried out after
hematoxylin–eosin staining, and the nature of the lesions was histologically
conﬁrmed in all cases (presence of glands and stroma).
Immunohistochemical analysis
Preselection of anti-human aromatase antibody
The speciﬁcity of four anti-human aromatase antibodies, used in previous
endometriosis studies (Fazleabas et al., 2003; Bukulmez et al., 2007;
Fechner et al., 2007), was evaluated by western blot on placental
protein extracts [1/250; horseradish peroxidase (HRP)-conjugated goat
anti-mouse secondary antibodies, 1/10 000; 40 mg of protein charged in
each lane].
Two rabbit polyclonal antibodies (BioVision Research Products, Moun-
tain View, CA, USA; Abcam, Cambridge, UK) were excluded, as their
speciﬁcity could not be conﬁrmed. Indeed, a second band was observed
in our protein extracts at 35 kDa. Sequencing (Eurogentec S.A., Seraing,
Belgium) of this band showed that it was not due to degradation products,
as hypothesized on the BioVision data sheet (data not shown).
Two mouse monoclonal anti-human aromatase antibodies [Acris Anti-
bodies, Hiddenhausen, Germany (here denoted AbI); and AbD Serotec,
Oxford, UK (here denoted AbII)] were shown to be speciﬁc, since only
one band (around 55 kDa) was detected. This band was sequenced (Euro-
gentec S.A.) and was shown to correspond to aromatase (data not
shown). They were developed in 2002 (Turner et al., 2002) and are
directed against a conserved epitope of aromatase corresponding to
amino acids 376–390 of the human aromatase sequence (KALEDDVID-
GYPVKK, sequence compared with the aromatase sequence stored in
the GenPept database: nP_000094). It was therefore decided to use
only monoclonal antibodies in this study.
Aromatase immunohistochemistry
Tissue sections were deparafﬁnized in Histosafe (YVSOLAB S.A., Beerse,
Belgium), hydrated in isopropanol (Merck, Darmstadt, Germany), washed
brieﬂy in water and incubated in hydrogen peroxide (Merck) 3% v/v in
methanol (Merck) for 30 min to block endogenous peroxidase activity.
Slides were rinsed in water and heat epitope retrieval was performed
using Target Retrieval Solution, pH 9.0 (Dako, ViaReal Carpinteria CA,
USA)þ0.1% Tween 20 (Sigma-Aldrich, Steinheim, Germany) for 20 min
at 968C. Sections were rinsed in phosphate-buffered saline (PBS)/
Tween 20 and non-speciﬁc reactions were blocked using bovine serum
albumin (BSA) 5% (Sigma-Aldrich)þnon-fat dry milk 2% (BioRad,
Hercules, CA, USA) in hypersaline Tris buffer (pH 7.4) for 1 h at room
temperature (RT). Endogenous biotin blocking was performed using the
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Biotin Blocking System (Dako) as follows: avidin solution was incubated for
10 min at RT and sections were rinsed in PBS/Tween 20. Thereafter,
biotin solution was incubated for 10 min at RT and sections were
washed in PBS/Tween 20. Sections were incubated with anti-aromatase
antibodies diluted 1 : 50 (AbI and AbII) in BSA 2.5%þnon-fat dry milk
1% in hypersaline Tris buffer (pH 7.4) overnight at 48C. Biotinylated
rabbit anti-mouse secondary antibodies (Dako) were then diluted 1:100
in BSA 2.5%þnon-fat dry milk 1% in hypersaline Tris buffer (pH 7.4)
and incubated with the tissue sections for 30 min at RT. Bound antibodies
were visualized by incubating the sections with avidin–biotin complex/
HRP (ABC/HRP) reagent (Vector Laboratories, Inc., Burlingame, CA,
USA) for 15 min at RT, followed by incubation with 3.30-diaminobenzidine
(Dako) for a further 15 min at RT. Sections were ﬁnally counterstained
with Mayer’s hemalum solution (Merck).
Human placental and ovarian tissues were utilized as positive controls
for aromatase expression (Turner et al., 2002). Negative control sections
were processed using non-speciﬁc IgG, or omitting the speciﬁc primary
antibodies.
Staining of iron deposits
Ferric iron deposits were evidenced in ovarian endometriotic lesions using
Perls’ Prussian blue staining (Perls, 1867). Brieﬂy, dewaxed 5 mm-thick
lesion sections were stained for 20 min in a solution of 1% kalium hexacya-
noferrate and 2% (v/v) hydrochloric acid and nuclei were counterstained
with nuclear fast red.
PCR and Q-PCR studies
Samples were homogenized in TRIzol reagent (Life Technologies,
Gaithersburg, MD, USA) using an Ultra-Turrax T25 homogenizer (Janke
and Kunkel, Brussels, Belgium). RNA quality was checked by spectropho-
tometry and analysis of the 28S:18S ratio after agarose gel electrophoresis.
Total RNA was isolated using the classic chloroform extraction and iso-
propanol precipitation method. Total RNA (2.5 mg) was reverse tran-
scribed with random hexamers (Eurogentec S.A.) and SuperScript RT
RNase H2 reverse transcriptase (Life Technologies).
Three sets of primers (localized in a conserved aromatase sequence
site) and three PCR protocols were applied.
A ﬁrst aromatase sequence of interest was ampliﬁed by PCR (protocol
I) using cDNA recovered from 15 patients undergoing laparoscopy. The
following primers were used (Fechner et al., 2007): TGG CTA CCC
AGT GAA AAA GG (forward); CCA TGG CGA TGT ACT TTC CT
(reverse) (amplicon length: 181 bp). The ampliﬁcation program involved
the following steps: 2 min at 948C, 35 cycles of 15 s at 948C, 30 s at
568C and 15 s at 728C, culminating in a ﬁnal step of 2 min at 728C. The
generated PCR products were size-fractionated on 2% agarose gel and
detected by ethidium bromide staining.
In a second set of experiments, other sequences of interest were ampli-
ﬁed by Q-PCR (protocol II) using cDNA recovered from 30 patients. The
following primers were used (Heilier et al., 2006a, b): TGG ACA CCT
CTA ACA CGC TCT TC (forward, aromatase) and GCC ATC AAT
GAC CCC TTC ATT [forward, glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH)]; GAG CTT GCC ATG CAT CAA AA (reverse, aroma-
tase) and TGA CGG TGC CAT GGA ATT T (reverse, GAPDH). The
ampliﬁcation program involved the following steps: 10 min at 958C, 40
cycles of 15 s at 958C and 1 min at 608C. Finally, the temperature was
gradually raised (0.18C/s) from 658C to 958C for melting curve analysis
to conﬁrm the speciﬁcity of the ampliﬁcation. Amplicon sizes (93 bp for
aromatase and 88 bp for GAPDH) were veriﬁed on 1% agarose gel, and
the aromatase amplicon was checked by sequencing (sequence compared
with the aromatase sequence stored in the GenBank database:
nM_000103). Q-PCR was performed using SYBR Green staining
(Applied Biosystems, Foster City, CA, USA) with a 7000 Sequence Detec-
tion System (Applied Biosystems), according to the manufacturer’s proto-
col. Aromatase expression was normalized to that of GAPDH, which was
previously shown to be expressed independently of the phase of the men-
strual cycle (Brosens et al., 2004).
TaqMan ampliﬁcation was also carried out (protocol III) (Dassen et al.,
2007), using cDNA recovered from 19 patients. Primers and probes for
aromatase (Hs00240671-m1) were purchased from Applied Biosystems
as pre-developed assays. Human cyclophilin A (Hs99999904-m1) was
selected as an endogenous RNA control. All PCR reactions were per-
formed using a 7000 Sequence Detection System (Applied Biosystems).
The ampliﬁcation program involved the following steps: 10 min at 958C,
40 cycles of 15 s at 958C and 1 min at 608C.
Q-PCR experiments (protocols II and III) were performed for each
sample in duplicate. A standard curve was generated using ﬁve dilutions
of plasmid constructions (from 100 000 to 10 copies of the aromatase
gene). Q-PCR efﬁciency was always higher than 0.98.
Results
In this study, aromatase expression was investigated in three distinct
endometriotic entities (peritoneal, ovarian and rectovaginal endome-
triotic lesions) and their matched endometrium. The histological
characteristics of endometriosis were always conﬁrmed after
hematoxylin–eosin staining by an experienced pathologist.
Aromatase immunohistochemistry set-up
The speciﬁcity of the primary antibodies was tested by western blot-
ting. Only one band (55 kDa) corresponding to aromatase was
detected in human placental protein extracts with AbI (Fig. 1A, lane
1) and AbII. In a preliminary experiment conducted in our laboratory,
only one band was observed in mature testicular protein samples too
(data not shown).
Aromatase immunohistochemistry was performed on
parafﬁn-embedded tissue using the avidin–biotin ampliﬁcation
system, as applied in previous studies (Kitawaki et al., 1997; Turner
et al., 2002; Fazleabas et al., 2003; Ishihara et al., 2003; Velasco et al.,
2006; Acien et al., 2007; Bukulmez et al., 2007; Fechner et al., 2007;
Hudelist et al., 2007). However, endogenous biotin was labeled in
the epithelial lining of endometriotic glands incubated with (Fig. 1B)
or without (Fig. 1C) primary antibody (AbI and AbII). An endogenous
biotin blocking step was therefore added before incubation with




As observed in previous studies, placental syncytiotrophoblasts
(Fig. 1D), granulosa and internal theca cells of pre-ovulatory follicles
(Fig. 1E and F), and luteal cells of corpus luteum (Fig. 1G) were
found to stain positive for aromatase.
All endometriotic lesions (19 peritoneal, 19 ovarian and 20 rectova-
ginal with AbI; 34 peritoneal, 34 ovarian and 30 rectovaginal with
AbII), their matched eutopic endometrium (48 with AbI; 63 with
AbII), and endometrium from disease-free patients (n ¼ 10) were
found to be aromatase-negative in both the glandular and stromal
compartments (Table I, Fig. 2A–D).
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As expected, on endometrioma sections, granulosa cells and
internal theca cells from pre-ovulatory follicles were shown to be
aromatase-positive. Non-speciﬁc stromal staining was also observed
on these sections (Fig. 2E). This was due to iron deposition, as
assessed by an experienced pathologist and conﬁrmed by Perls’ stain-
ing (Fig. 2F).
Preliminary results obtained by western blot with AbI and AbII on
protein extracted from endometriotic lesions and their matched
eutopic endometrium (10 peritoneal lesions, 2 ovarian lesions, 3 rec-
tovaginal lesions, 8 eutopic endometrium; mean age of patients:
28.4+5.4 years; proliferative phase: 7; secretory phase: 5; spon-
taneous cycles: 5; estroprogestin treatment: 7; GnRH analog
therapy: 1) showed an absence of aromatase protein in these
samples (Fig. 1A, lanes 2–9), conﬁrming the immunohistochemical
results.
Aromatase gene expression (PCR and Q-PCR) in endometriotic
lesions
An initial PCR study (35 cycles) was conducted with a ﬁrst set of
primers (Fig. 3A). Although a band was detected in placental mRNA
extracts, no aromatase expression was observed in endometriotic
lesions (8 peritoneal, 8 ovarian and 8 rectovaginal) or matched
eutopic endometrium (n ¼ 15) (Table II).
Q-PCR analysis (increased to 40 cycles) was therefore performed
on mRNA extracted from other endometriotic lesions (11 peritoneal,
11 ovarian and 17 rectovaginal) and their matched eutopic
Figure 1 Aromatase immunohistochemistry set-up.
Western blot performed on protein extracts recovered from human placental tissue (lane 1), peritoneal endometriotic lesions (lanes 2, 4, 6, 8, 9) and eutopic endome-
trium from endometriosis patients (lanes 3, 5, 7) with mouse monoclonal anti-aromatase antibody (AbI, 1/250; HRP-conjugated goat anti-mouse secondary antibodies, 1/
10 000, 40 mg of protein charged in each lane) (A). Aromatase immunohistochemistry (AbI) of a peritoneal endometriotic lesion without endogenous biotin blocking (B),
and its negative control (C). Aromatase immunohistochemistry of human placental sections (D) and human ovary sections (E–G). Original magniﬁcation: 200 (B–G),
scale bars ¼ 100.0 mm.
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endometrium (n ¼ 30), with other sets of primers (Fig. 3B). Discern-
ible levels (near the detection limit) were found in almost all the endo-
metriomas tested (10/11; mean aromatase CT: 35.0+ 1.9; mean
GAPDH CT: 20.4+1.2), in a few samples of peritoneal (1/11) and
rectovaginal (3/17) endometriotic lesions, and in one sample of
eutopic endometrium (1/30) (Table II).
Figure 2 Aromatase immunohistochemistry of human endometrium and endometriotic lesions, and iron deposit staining.
Aromatase immunohistochemistry (AbI) of eutopic endometrium from disease-free patients (A), peritoneal lesions (B), ovarian lesions (C) and rectovaginal lesions (D).
Aromatase immunohistochemistry (E) and Perls’ staining (F) of endometrioma sections. Original magniﬁcation: 200, scale bars ¼ 100.0 mm.
..................................................... .....................................
.............................................................................................................................................................................................
Table I Summary of immunohistochemical results
Spontaneous Hormonal treatment
Proliferative Secretory EP GnRHa
AbI Peritoneal endometriosis 0/9 0/7 0/3 0/0
Ovarian endometriosis 0/6 0/9 0/4 0/0
Rectovaginal endometriosis 0/0 0/6 0/13 0/1
Eutopic endometrium 0/14 0/20 0/13 0/1
Disease-free endometrium 0/7 0/3 0/0 0/0
AbII Peritoneal endometriosis 0/13 0/11 0/9 0/1
Ovarian endometriosis 0/10 0/13 0/10 0/1
Rectovaginal endometriosis 0/4 0/8 0/16 0/2
Eutopic endometrium 0/18 0/24 0/19 0/2
Disease-free endometrium 0/7 0/3 0/0 0/0
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A third analysis was conducted with TaqMan probes (Fig. 3C).
Again, discernible levels were found in almost all the endometriomas
tested (10/13; mean aromatase Ct: 34.6+2.0; mean cyclophilin A
Ct: 25.5+0.6), in a few samples of peritoneal endometriotic
lesions (4/11), and in one sample of eutopic endometrium (1/17).
No aromatase expression was detected in rectovaginal endometriotic
lesions (Table II).
Plasmids were constructed and Q-PCR was applied to determine
the limit of detection (according to the procedure described on the
Applied Biosystems website: http://www3.appliedbiosystems.com/
cms/groups/mcb_marketing/documents/generaldocuments/cms_04
2486.pdf). This corresponds to the Ct value of samples containing 10
molecules of mRNA of genes of interest (aromatase SYBR Green:
38.0; GAPDH SYBR Green: 38.1; aromatase TaqMan: 37.6; cyclophi-
lin A TaqMan: 38.2).
Discussion
In endometriosis, aromatase is thought to be involved in a positive
feedback loop that favors expression of key steroidogenic genes
(Bulun et al., 2005). According to this hypothesis, estrogen stimulates
production of the cyclooxygenase type 2 (COX-2) enzyme, resulting
in elevated levels of prostaglandin E2 (PGE2), which is a potent stimu-
lator of aromatase activity in endometriosis. This leads to continuous
local production of E2 and PGE2 in endometriotic tissue. Estrogen
enhances the growth and invasion of endometriotic tissue, while
Figure 3 Aromatase mRNA expression.
Aromatase mRNA expression with protocol I (A) in placental tissue (lanes 1 and 12), eutopic endometrium from endometriosis patients (lanes 2, 6, 10, 11), and ovarian
(lane 3), peritoneal (lanes 4, 5, 7) and rectovaginal (lanes 8 and 9) endometriotic lesions. Aromatase mRNA expression with protocol II (B) and III (C).
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prostaglandins mediate pain, inﬂammation and infertility (Bulun et al.,
2005). This molecular link between inﬂammation and estrogen pro-
duction could be responsible in part for the devastating symptoms
of endometriosis.
The main objective of this study was to precisely localize (stromal
and/or glandular tissue) and quantify aromatase expression in three
distinct types of endometriotic lesions (peritoneal, ovarian and recto-
vaginal) by immunohistochemistry and Q-PCR. No aromatase protein
was detected in the glands or stroma of any lesions by immunohisto-
chemistry, while Q-PCR revealed only low aromatase mRNA levels in
endometriomas, and barely detectable levels in a few peritoneal and
rectovaginal endometriotic lesions and eutopic endometrium samples.
Our method of immunostaining was validated by several positive
control tissues. Indeed, aromatase staining was found in human
placental syncytiotrophoblasts, granulosa and internal theca cells of
pre-ovulatory follicles, and luteal cells from corpus luteum. Similarly,
pre-ovulatory follicles sometimes observed on endometrioma sections
showed positive aromatase staining.
The speciﬁcity of anti-human aromatase antibodies was conﬁrmed
by western blot on human placental protein extracts, since a band cor-
responding to aromatase (55 kDa) was detected with AbI and AbII,
while a complete absence of bands was observed in endometriotic
lesion protein extracts, conﬁrming our immunohistochemical results.
Our study showed low levels of aromatase mRNA expression in
ovarian endometriotic lesions, as observed in our previous studies
(Heilier et al., 2006a, b). This was probably due to the presence of fol-
licular cells in the biopsies. Indeed, follicles are known to have high
aromatase levels before ovulation (Sasano et al., 1989), which was
also evidenced in our immunohistochemical results.
The ﬁndings of the present study contradict most of the existing lit-
erature on the subject. Indeed, in published studies, aromatase was
detected by immunohistochemistry (Kitawaki et al., 1997, 1999a, b;
Ishihara et al., 2003; Wo¨lﬂer et al., 2005; Velasco et al., 2006; Acien
et al., 2007; Bukulmez et al., 2007; Hudelist et al., 2007) and
Q-PCR (Noble et al., 1996; Dheenadayalu et al., 2002; Ishihara
et al., 2003; Heilier et al., 2006a, b; Matsuzaki et al., 2006; Dassen
et al., 2007; Kyama et al., 2007; Smuc et al., 2007; Attar et al.,
2008; Smuc et al., 2008; Aghajanova et al., 2009) in both eutopic
and ectopic endometrium from endometriosis patients, but not in
eutopic endometrium from disease-free women. Nevertheless,
there are discrepancies between many of these immunohistochemical
studies, since some papers report stromal aromatase localization in
human endometriotic lesions (Wo¨lﬂer et al., 2005; Velasco et al.,
2006; Acien et al., 2007) and lesions induced in baboons (Fazleabas
et al., 2003), while others demonstrate glandular aromatase localiz-
ation in human endometriotic lesions (Kitawaki et al., 1997, 1999a,
b; Ishihara et al., 2003; Wo¨lﬂer et al., 2005; Hudelist et al., 2007)
and lesions induced in mice (Fechner et al., 2007). Glandular aroma-
tase expression was also evidenced by laser capture microdissection
in human endometriotic lesions (Matsuzaki et al., 2006). However, a
recent paper reported an absence of aromatase activity in endome-
triotic samples (Delvoux et al., 2008).
In our immunohistochemical analysis, glandular staining was based on
avidin–biotin ampliﬁcation, as in most papers showing aromatase
protein localization in endometriosis (Turner et al., 2002; Fazleabas
et al., 2003; Velasco et al., 2006; Acien et al., 2007; Fechner et al.,
2007; Hudelist et al., 2007). Since we also detected labeling in our nega-
tive controls (endometriotic lesions without primary antibody), we
added an endogenous biotin blocking step to our protocol before incu-
bation with primary antibody (only previously done by Turner et al.,
2002). This resulted in the disappearance of glandular staining. We
therefore suggest that what some authors took to be aromatase
protein in endometriotic lesions was actually endogenous biotin.
Moreover, similar staining to that found by other authors in human
endometriotic lesions (Velasco et al., 2006; Acien et al., 2007) and
induced endometriotic lesions in baboons (Fazleabas et al., 2003)
was observed on our endometrioma sections. These authors con-
sidered this staining to be evidence of stromal localization of aroma-
tase. However, on our sections, the presence of siderophages or
iron deposits was suspected and subsequently conﬁrmed by Perls’
staining. Indeed, the same surface areas were labeled with both stains.
Concerning PCR detection, Heilier et al. previously showed aroma-
tase expression to be higher in endometriomas than in peritoneal and
rectovaginal endometriotic lesions (Heilier et al., 2006a, b). However,
the majority of results were obtained after 40 cycles of ampliﬁcation
(up to 55 cycles) and the Ct values could well have resulted from
.................................................... ....................................
.............................................................................................................................................................................................
Table II Summary of PCR and Q-PCR studies
Spontaneous Hormonal treatment
Proliferative Secretory EP GnRHa
Protocol I Peritoneal endometriosis 0/4 0/3 0/1 0/0
Ovarian endometriosis 0/4 0/3 0/1 0/0
Rectovaginal endometriosis 0/3 0/2 0/2 0/1
Eutopic endometrium 0/6 0/4 0/4 0/1
Protocol II Peritoneal endometriosis 0/2 0/1 1/5 0/3
Ovarian endometriosis 1/1 1/2 6/6 2/2
Rectovaginal endometriosis 0/5 0/3 3/9 0/2
Eutopic endometrium 0/6 0/4 1/14 0/6
Protocol III Peritoneal endometriosis 2/4 0/2 2/5 0/0
Ovarian endometriosis 3/4 2/3 5/6 0/0
Rectovaginal endometriosis 0/2 0/2 0/6 0/0
Eutopic endometrium 0/5 0/4 1/8 0/0
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non-speciﬁc ampliﬁcation. We therefore conducted new Q-PCR
analysis with the same primers, but stopping mRNA ampliﬁcation at
40 cycles, and included additional controls (analysis of mRNA
quality, sequencing of ampliﬁcation products, standard curve analysis
with dilutions of plasmid constructions and limit of detection determi-
nation). We then checked the dissociation curves (only one peak
observed for each sample) and Q-PCR efﬁciency (always higher than
0.98). The amplicon ampliﬁed with this protocol (protocol II) was
also sequenced and conﬁrmed. Nevertheless, we only detected low
levels of aromatase in our endometrioma samples. As conﬁrmed by
our immunohistochemical results, these low levels were probably
due to follicular cells contaminating the biopsies. Barely detectable
levels of aromatase were also found in a few peritoneal and rectova-
ginal endometriotic lesions, and in some eutopic endometrium
samples. Although the lesions were carefully dissected, one cannot
exclude contamination by surrounding tissues, such as adipose tissue
or intact peritoneum (Simpson et al., 1994; Kyama et al., 2007),
which may account for the occurrence of a few aromatase mRNA
copies in these samples.
Our study investigated a broad range of patients (in proliferative or
secretory phases, treated with estroprogestins or GnRH analogs), and
low levels of aromatase expression detected by Q-PCR were found in
non-treated as well as treated patients, indicating that treatment and
cycle phase had no impact on our results.
The present study, showing an absence of aromatase expression at
both the protein and mRNA levels, is furthermore corroborated by a
recent publication by Delvoux et al., who used a different technique
but obtained similar results. Indeed, they were also unable to detect
aromatase activity in their endometriotic samples (Delvoux et al.,
2008).
The good results obtained with AIs in clinical trials for endometrio-
sis treatment should therefore be reinterpreted in the light of our data.
The beneﬁcial effects of AIs may well be explained by a systemic
response or by inhibition of estrogen production in intraperitoneal
tissues, such as intact peritoneum (Kyama et al., 2007) or adipose
tissue, rather than inhibition in endometriotic lesions themselves
(Bulun et al., 2005). Although aromatase levels per adipose tissue
ﬁbroblast or peritoneal cell may be small, the sum of estrogen
arising from all these cells in the peritoneal cavity could have an
impact on endometriotic lesion development.
In conclusion, our results failed to conﬁrm previously published
studies on aromatase expression in human endometriotic lesions.
Indeed, we observed no aromatase protein in the glandular or
stromal compartments of ectopic endometrial tissue, and barely
detectable aromatase mRNA expression, suggesting that locally pro-
duced aromatase (within endometriotic lesions) could be less impli-
cated than previously postulated.
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